Amphetamine 3.1mg, 6.3mg, 9.4mg, 12.5mg, 15.7mg, 18.8mg; ext-rel orally disintegrating tabs. Do not substitute for other amphetamine products on a mg-per-mg basis ...
When switching from other amphetamine-containing products, discontinuation of treatment followed by slow titration with ...
ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 1% to $15.3 million versus $15.1 million in Q1 fiscal 2024. Pediatric Portfolio (Karbinal® ER, Poly-Vi-Flor® and Tri ...
Other ADHD products in its portfolio include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Adzenys-ER (amphetamine) extended-release oral suspension. The company ...
Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist.
ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 1% to $15.3 million versus $15.1 million in Q1 fiscal 2024. Pediatric Portfolio (Karbinal® ER, ...
Q1 2025 Highlights ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 1% to $15.3 million versus $15.1 million in Q1 fiscal 2024. Pediatric Portfolio (Karbinal® ER, ...